Using Tc-99m Hmpao Brain Spect to Evaluate the Effects of Anticoagulant Therapy on Regional Cerebral Blood Flow in Primary Antiphospholipid Antibody Syndrome Patients with Brain Involvement - a Preliminary Report
Resource
RHEUMATOLOGY INTERNATIONAL v.23 n.6 pp.301-304
Journal
RHEUMATOLOGY INTERNATIONAL
Journal Volume
v.23
Journal Issue
n.6
Pages
301-304
Date Issued
2003
Date
2003
Author(s)
YEN, RUOH-FANG
Abstract
Technetium-99m hexamethylpropylene amine oxime (Tc-99m HMPAO ) brain single photon emission computed tomography (SPECT) was used to evaluate the effects of anticoagulant therapy ( ACT) on regional cerebral blood flow (rCBF) in patients with primary antiphospholipid antibody syndrome ( PAPS). Sixteen female PAPS patients with neuropsychiatric manifestations and hypoperfusion lesions demonstrated on initial Tc-99m HMPAO brain SPECT images were enrolled in this study. Follow -up Tc-99m HMPAO brain SPECT images were performed 1 month after ACT. Meanwhile, serum anticardiolipin antibodies (ACA) were measured before and after ACT. Before ACT, 14 (87.5% ) patients had positive ACA. After ACT, all 16 PAPS patients showed decreased serologic findings, and their neuropsychiatric manifestations subsided . After ACT, 11 (68 .8%) patients showed complete recovery of regional cerebral blood flow (rCBF) and five (31.2%) patients showed partial recovery in the follow-up Tc-99m HMPAO brain SPECT images. This type of imaging is a logical and objective tool for measuring the effects of ACT in PAPS patients with brain involvement by determining changes in rCBF.
Subjects
anticoagulant therapy
primary antiphospholipid antibody syndrome regional cerebral
Tc-99m HMPAO brain SPECT